FDA Warning Letters

Covers major FDA compliance actions, analysis of warning letters, common pitfalls.

April 16, 2025
Takeaway -

OTC Topical “Inactive” Ingredient Marketing Claims “Extra” claims are often non-compliant

April 9, 2025
Takeaway -

Use FDA’s helpful resource (Criterion 2)

April 2, 2025
Takeaway -

A look at the manufacturing and quality process

March 26, 2025
Takeaway -

Brands should monitor influencer posts for compliance

March 19, 2025
Takeaway -

Curated testimonials are marketing claims

March 12, 2025
Takeaway -

Distributors are responsible for the products they distribute

March 5, 2025
Takeaway -

Following specifications prevents greater issues

February 26, 2025
Takeaway -

Disclosing material connection is essential for compliance

February 19, 2025
Takeaway -

Take FDA inquiries seriously

February 12, 2025
Takeaway -

Ensure ESG claims are substantiated

February 5, 2025
Takeaway -

Small issues signify deeper noncompliance

January 29, 2025
Takeaway -

Small words can drastically increase claim risk